ERBB2 and breast carcinoma: The cell lines chosen for analyzing anti-survival effects of these drugs represented the clinically relevant subtypes of breast cancer, i.e., non-TNBC with luminal and HER2+ breast cancer cells as well as TNBC without and with BRCA1 mutation.